's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » ***PKTX..The Show is About to Start..

 - UBBFriend: Email this page to someone!    
Author Topic: ***PKTX..The Show is About to Start..

Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
***PKTX…Protokinetix Investors.. To see the amount of the present ongoing research projects that has been initiated in just the last few years is amazing.
…. This momentum started slowly and Now…Is gaining speed.. These four projects are slated to begin in very near future before the end of the 2017..

****Starting to look like a very Merry Holiday Season.. :+)

...Kidney Ischemia (anticipated start date 4th quarter 2017)

Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted. This condition can affect any part of the human body. When this circumstance transpires, cell death and organ damage follows very rapidly. Ischemia is a major cause of kidney damage, heart attacks and strokes.

Our testing is to determine whether AAGP™ can reduce the inflammatory response that causes cell damage and organ failure that occurs during an ischemic attack.

...Monoclonal Antibody Production (anticipated start date 4th quarter 2017)

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope. The use of monoclonal antibodies to treat diseases is called immunotherapy because each type of monoclonal antibody will target a specific targeted antigen in the body. Monoclonal antibodies are currently being used to treat Cancer, Rheumatoid Arthritis, Multiple Sclerosis, Cardiovascular Disease, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis, Transplant Rejection, and several more conditions.

By adding AAGP™ into the culture medium, we are hoping to show a substantial increase in viable monoclonal antibodies that could lead to a dramatic decrease in the cost of production of monoclonal antibody medicines.

...Ischemic Stroke Repair (anticipated start 4th quarter 2017)

Ischemic Stroke is usually associated with severe disabilities, high recurrence rate and other poor outcomes. Currently, there are no long-term effective treatments for stroke. Cell therapies have been explored previously. However, the therapeutic outcomes are often limited by poor survival of transplanted cells, difficult delivery, uncontrolled cell differentiation, ineffective engraftment with host tissues and non-sustained delivery of growth factors.

We will be testing to demonstrate that the AAGP™ molecule suppresses the inflammatory attack caused by ischemic stroke thereby preventing any long term damage to the human body.

…Immune Cell Cryopreservation Recovery (started June 2017 - anticipated end date 4th quarter 2017)

Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. The ability to use immune cells provides an oncologist another major tool in their arsenal to fight cancer.

Posts: 142 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2018 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2